Resproly

About Resproly

Resproly, established in 2018, is a biopharmaceutical company headquartered in Shenzhen, China, with significant operations in Zhuhai. The company was founded by Dr. Chen Yongqi, who serves as Chairman and Chief Scientist. Dr. Chen holds a PhD in Chemical Engineering from the University of Cambridge and has over 15 years of experience in the inhalation drug sector, notably as a pharmaceutical expert at Vectura in the UK, where he led the development of several major international drugs. His expertise is central to Resproly's mission to address the gap between China's capabilities and those of developed nations in inhalation drug technology.

The firm concentrates on the research, development, and production of drug-device combination products for treating respiratory and other significant diseases. Its core business revolves around creating inhaled therapies for conditions with high clinical needs, such as asthma, chronic obstructive pulmonary disease (COPD), Parkinson's disease, and diabetes. The business model is centered on developing a pipeline of pharmaceutical products and monetizing them through clinical progression and market launch. Resproly operates in a market historically dominated by large multinational corporations, aiming to capture a share by leveraging its specialized technical capabilities.

Resproly has established four primary R&D and production platforms: metered-dose inhalation (MDI), dry powder inhalation (DPI), nebulizers, and nasal sprays. These platforms enable the development of complex inhalation products. For instance, the DPI technology involves micronized drugs inhaled by the patient using a special device, while the MDI platform uses a propellant to dispense medicated solutions or suspensions in an aerosolized mist. The company has secured significant funding to advance its pipeline, including a Series A round of 50 million RMB in 2019, a Series B of nearly CNY 200 million in February 2021, and a Series B+ of over CNY 100 million in May 2022. These funds are allocated to advancing clinical research, expanding its professional teams, and developing new drugs, with several products moving into clinical trials.